nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

01.11.2010 | Fertility Preservation

Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat

verfasst von: Alison Y. Ting, Brian K. Petroff

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

We serendipitously observed a protective effect of tamoxifen against depletion of ovarian follicles by 7,12-dimethylbenzanthracene (DMBA), a chemical carcinogen, during a cancer prevention study. Such ovarian protection is being sought as an alternative approach to fertility preservation in human cancer patients.

Methods

Rats received tamoxifen (0, 1 mg or 2.5 mg/kg/d) and DMBA (0, 1, 2 mg/kg/wk) or cyclophosphamide (0, 35, 50 mg/kg/wk). Ovarian follicles were quantified and effects on fertility and litter size were tested. Cultured oocytes were exposed to chemotherapy drug doxorubicin, with or without 4-hydroxytamoxifen (4HT).

Results

DMBA and cyclophosphamide decreased the number of primordial and total follicles, and this reduction was prevented by tamoxifen. Cyclophosphamide tended to reduce fertility and lessened neonatal survival. Tamoxifen reversed these defects. Doxorubicin caused oocyte fragmentation which was prevented by 4HT.

Conclusions

Tamoxifen decreases follicle loss and improves reproductive function following exposure to ovarian toxicants including chemotherapy drugs in the female rat.

Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, et al. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod. 2008;23:2506–12.PubMedCrossRef

Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin. 2005;55:211–28.PubMedCrossRef

Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169:123–31.PubMedCrossRef

Pacey AA. Fertility issues in survivors from adolescent cancers. Cancer Treat Rev. 2007;33(7):646–55.PubMedCrossRef

Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353(1):64–73.PubMedCrossRef

Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52(2):365–72.PubMedCrossRef

Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044–54.PubMedCrossRef

Blumenfeld Z. GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabetes Obes. 2008;15(6):523–8.PubMedCrossRef

Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229–39.PubMedCrossRef

10.

Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12(9):1055–66.PubMedCrossRef

11.

Ting AY, Kimler BF, Fabian CJ, Petroff BK. Tamoxifen prevents premalignant changes of breast but not ovarian cancer in rats at high risk for both disease. Cancer Prev Res. 2008;1:546–54.CrossRef

12.

Kossoy G, Ben-Hur H, Elhayany A, Schneider DF, Kossoy N, Zusman I. Effects of tamoxifen and soluble tumor-associated antigens on ovarian structure in mammary tumor-bearing rats. Oncol Rep. 2005;14(5):1317–21.PubMed

13.

Geyer RP, Bleisch VR, Bryant JE, Robbins AN, Saslaw IM, Stare FJ. Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-1,2-benzanthracene. Cancer Res. 1951;11(6):474–8.PubMed

14.

Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet. 2001;28(4):355–60.PubMedCrossRef

15.

Borman SM, Christian PJ, Sipes IG, Hoyer PB. Ovotoxicity in female Fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic hydrocarbons: comparison through calculation of an ovotoxic index. Toxicol Appl Pharmacol. 2000;167(3):191–8.PubMedCrossRef

16.

Tsai-Turton M, Nakamura BN, Luderer U. Induction of apoptosis by 9, 10-dimethyl-1, 2-benzanthracene in cultured preovulatory rat follicles is preceded by a rise in reactive oxygen species and is prevented by glutathione. Biol Reprod. 2007;77(3):442–51.PubMedCrossRef

17.

Shiromizu K, Thorgeirsson SS, Mattison DR. Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6 N and DBA/2 N mice. Pediatr Pharmacol (New York). 1984;4(4):213–21.

18.

Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985;45(8):3651–6.PubMed

19.

Jurisicova A, Lee HJ, D’Estaing SG, Tilly J, Perez GI. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ. 2006;13(9):1466–74.PubMedCrossRef

20.

Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15(10):1179–85.PubMedCrossRef

21.

Oh SH, Miyoshi K, Funahashi H. Rat oocytes fertilized in modified rat 1-cell embryo culture medium containing a high sodium chloride concentration and bovine serum albumin maintain developmental ability to the blastocyst stage. Biol Reprod. 1998;59(4):884–9.PubMedCrossRef

22.

Perez GI, Tao XJ, Tilly JL. Fragmentation and death (a.k.a. apoptosis) of ovulated oocytes. Mol Hum Reprod. 1999;5(5):414–20.PubMedCrossRef

23.

Tilly JL. Ovarian follicle counts–not as simple as 1, 2, 3. Reprod Biol Endocrinol. 2003;1:11.PubMedCrossRef

24.

Stern JM, Strait T. Reproductive success, postpartum maternal behavior, and masculine sexual behavior of neonatally androgenized female hamsters. Horm Behav. 1983;17(2):208–24.PubMedCrossRef

25.

Jakubowski M, Terkel J. Female reproductive function and sexually dimorphic prolactin secretion in rats with lesions in the medial preoptic-anterior hypothalamic continuum. Neuroendocrinology. 1986;43(6):696–705.PubMedCrossRef

26.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.PubMedCrossRef

27.

Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin’s lymphoma: an interim analysis of a randomized phase III trial. Med Oncol. 2000;17(1):39–46.PubMedCrossRef

28.

Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia. 1995;9(10):1631–7.PubMed

29.

Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117(3):561–7.PubMedCrossRef

30.

Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, Giorda G, et al. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit. 2007;29(3):349–52.PubMedCrossRef

31.

Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980;40(11):4043–7.PubMed

32.

Hu X, Christian P, Sipes IG, Hoyer PB. Expression and redistribution of cellular Bad, Bax, and Bcl-X(L) protein is associated with VCD-induced ovotoxicity in rats. Biol Reprod. 2001;65(5):1489–95.PubMedCrossRef

33.

Livera G, Petre-Lazar B, Guerquin MJ, Trautmann E, Coffigny H, Habert R. p63 null mutation protects mouse oocytes from radio-induced apoptosis. Reproduction. 2008;135(1):3–12.PubMedCrossRef

34.

Morita Y, Perez GI, Maravei DV, Tilly KI, Tilly JL. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol Endocrinol. 1999;13(6):841–50.PubMedCrossRef

35.

Thompson KE, Sipes IG, Greenstein BD, Hoyer PB. 17beta-estradiol affords protection against 4-vinylcyclohexene diepoxide-induced ovarian follicle loss in Fischer-344 rats. Endocrinology. 2002;143(3):1058–65.PubMedCrossRef

36.

Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res. 1999;84(2):229–39.PubMed

37.

Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16(4):309–14.PubMedCrossRef

38.

fDarvari R, Boroujerdi M. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin. Cancer Chemother Pharmacol. 2005;56(5):497–509.PubMedCrossRef

39.

Shen LZ, Hua YB, Yu XM, Xu Q, Chen T, Wang JH, et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol. 2005;11(7):1060–4.PubMed

40.

Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.PubMedCrossRef

Titel: Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat
verfasst von: Alison Y. Ting
Brian K. Petroff
Publikationsdatum: 01.11.2010
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 11/2010
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-010-9463-y

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Bildnachweise

Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Frau klebt Pflaster auf den Oberschenkel/© svetikd / Getty Images / iStock (Symbolbild mit Fotomodell), Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Junge Frau untersucht Gewebeprobe/© luchschenF / Stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2010

Laboratory evaluation in oocyte cryopreservation suggests retrieved oocytes are comparable whether frozen for medical indications, deferred reproduction or oocyte donation

No mitochondrial DNA deletions but more D-loop point mutations in repeated pregnancy loss

The house that Professor Edwards built

Cryo-survival, fertilization and early embryonic development of vitrified oocytes derived from mice of different reproductive age